282 related articles for article (PubMed ID: 19165635)
1. A cellular viewpoint of anti-FVIII immune response in hemophilia A.
André S; Meslier Y; Dimitrov JD; Repessé Y; Kaveri SV; Lacroix-Desmazes S; Dasgupta S
Clin Rev Allergy Immunol; 2009 Oct; 37(2):105-13. PubMed ID: 19165635
[TBL] [Abstract][Full Text] [Related]
2. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.
Navarrete A; Dasgupta S; Delignat S; Caligiuri G; Christophe OD; Bayry J; Nicoletti A; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2009 Nov; 7(11):1816-23. PubMed ID: 19682235
[TBL] [Abstract][Full Text] [Related]
3. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.
Hartholt RB; Wroblewska A; Herczenik E; Peyron I; Ten Brinke A; Rispens T; Nolte MA; Slot E; Claassens JW; Nimmerjahn F; Verbeek JS; Voorberg J
J Thromb Haemost; 2017 Feb; 15(2):329-340. PubMed ID: 27868337
[TBL] [Abstract][Full Text] [Related]
4. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII.
Dimitrov JD; Dasgupta S; Navarrete AM; Delignat S; Repesse Y; Meslier Y; Planchais C; Teyssandier M; Motterlini R; Bayry J; Kaveri SV; Lacroix-Desmazes S
Blood; 2010 Apr; 115(13):2682-5. PubMed ID: 19890094
[TBL] [Abstract][Full Text] [Related]
5. Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.
Meslier Y; André S; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
Immunology; 2010 Dec; 131(4):549-55. PubMed ID: 20673239
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory antibodies in hemophilia A.
Pratt KP
Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
[TBL] [Abstract][Full Text] [Related]
7. Tolerating Factor VIII: Recent Progress.
Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
Front Immunol; 2019; 10():2991. PubMed ID: 31998296
[TBL] [Abstract][Full Text] [Related]
8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
10. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
Adair P; Su Y; Scott DW
Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
[TBL] [Abstract][Full Text] [Related]
11. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
12. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
13. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
14. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM
Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272
[TBL] [Abstract][Full Text] [Related]
15. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
16. Review of immune tolerance induction in hemophilia A.
Schep SJ; Schutgens REG; Fischer K; Boes ML
Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
[TBL] [Abstract][Full Text] [Related]
17. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice.
Gaitonde P; Ramakrishnan R; Chin J; Kelleher RJ; Bankert RB; Balu-Iyer SV
J Biol Chem; 2013 Jun; 288(24):17051-6. PubMed ID: 23649621
[TBL] [Abstract][Full Text] [Related]
18. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
[TBL] [Abstract][Full Text] [Related]
20. [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].
Ishiguro A
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):476-84. PubMed ID: 22214808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
